Residency · Residency · Neurology

Secondary Stroke Prevention: Antithrombotics and Risk Factor Management

Overview

Secondary prevention, when optimally implemented, reduces the risk of recurrent stroke by 60 to 80%. Treatment is guided by the underlying stroke mechanism, whether large artery atherosclerosis, cardioembolism, small vessel disease, or cryptogenic origin. Dual antiplatelet therapy has a defined role in the early period after high-risk TIA and minor stroke, and risk factor management addressing hypertension, dyslipidemia, diabetes, and lifestyle is at least as important as antithrombotic therapy itself.

Antithrombotic Therapy by Mechanism

Large Artery Atherosclerosis

Antiplatelet therapy is the first-line treatment. Options include aspirin 81-325 mg daily, clopidogrel 75 mg daily, or aspirin-dipyridamole extended release (25/200 mg twice daily). For patients presenting with minor stroke (NIHSS of 3 or less) or high-risk TIA, dual antiplatelet therapy with aspirin plus clopidogrel is recommended for 21 days, followed by transition to a single antiplatelet agent. Patients with high-grade carotid stenosis should be evaluated for revascularization with carotid endarterectomy or carotid artery stenting.

Cardioembolism (Atrial Fibrillation)

Anticoagulation is the standard of care, and direct oral anticoagulants are preferred over warfarin for non-valvular atrial fibrillation. Dabigatran, a direct thrombin inhibitor studied in RE-LY, at 150 mg twice daily is superior to warfarin for stroke prevention with similar bleeding rates. Rivaroxaban, a factor Xa inhibitor studied in ROCKET-AF, is non-inferior to warfarin. Apixaban, studied in ARISTOTLE, is superior to warfarin for both stroke prevention and bleeding risk, making it the preferred agent for many clinicians. Edoxaban, studied in ENGAGE AF-TIMI 48, is non-inferior to warfarin. For patients with mechanical heart valves or moderate-to-severe mitral stenosis, warfarin remains mandatory because DOACs are contraindicated in these settings. The timing of anticoagulation initiation after stroke is generally 4 to 14 days, based on infarct size and the risk of hemorrhagic transformation, though the ELAN trial supports early initiation within 48 hours for mild-to-moderate strokes.

Small Vessel Disease (Lacunar Stroke)

A single antiplatelet agent, either aspirin or clopidogrel, is recommended. The SPS3 trial demonstrated that dual antiplatelet therapy did not reduce recurrent stroke compared to aspirin alone but increased bleeding and mortality. Aggressive blood pressure control is the critical intervention, with the SPS3 blood pressure arm showing benefit with a target below 130 mmHg systolic.

Cryptogenic Stroke

Evaluation for occult atrial fibrillation with prolonged cardiac monitoring is essential. The CRYSTAL-AF trial showed that an implantable loop recorder detected atrial fibrillation in 30% of cryptogenic stroke patients at 3 years. Patients under 60 without another identified cause should be evaluated for a patent foramen ovale. In the absence of an identified source, default therapy is antiplatelet treatment.

Dual Antiplatelet Therapy (DAPT)

CHANCE Trial (2013, China)

CHANCE randomized patients with minor stroke or high-risk TIA to aspirin plus clopidogrel for 21 days versus aspirin alone, starting within 24 hours. The combination produced a 32% relative risk reduction in recurrent stroke at 90 days with no increase in major bleeding.

POINT Trial (2018, International)

POINT randomized similar patients to aspirin plus clopidogrel for 90 days versus aspirin alone, starting within 12 hours. While there was a significant reduction in ischemic events, major bleeding increased after day 21. Combined analysis of CHANCE and POINT data confirmed that the benefit of DAPT is concentrated in the first 21 days, while bleeding risk escalates beyond that point.

Current Recommendation

Dual antiplatelet therapy with aspirin plus clopidogrel should be given for 21 days after minor non-cardioembolic ischemic stroke or high-risk TIA, followed by transition to single antiplatelet therapy, typically clopidogrel monotherapy. CYP2C19 genotyping may be considered, as poor metabolizers of clopidogrel may benefit from ticagrelor instead; the THALES trial showed benefit of aspirin plus ticagrelor but with increased bleeding.

Patent Foramen Ovale (PFO) Closure

The Controversy

A PFO is present in approximately 25% of the general population and in 40 to 50% of patients with cryptogenic stroke. The central question is whether the PFO is an incidental finding or the actual cause of paradoxical embolism. Features suggesting a pathogenic PFO include large shunt size, the presence of an atrial septal aneurysm, Valsalva-associated events, young age, and the absence of traditional vascular risk factors.

Key Trials

CLOSE in 2017 showed PFO closure to be superior to antiplatelet therapy alone, with a 0% versus 6% recurrent stroke rate at 5 years in patients with large PFO or atrial septal aneurysm. RESPECT, with extended follow-up in 2017, demonstrated that PFO closure with the Amplatzer device reduced recurrent stroke compared to medical therapy. DEFENSE-PFO in 2018 confirmed superiority of closure in patients with high-risk PFO features. The PC Trial in 2013 did not show significant benefit but was likely underpowered.

Current Practice

PFO closure is recommended for patients aged 18 to 60 with cryptogenic stroke and high-risk PFO features such as a large shunt or atrial septal aneurysm. A thorough workup to exclude other stroke causes is mandatory before attributing the event to the PFO. After closure, patients receive dual antiplatelet therapy for 1 to 6 months followed by aspirin alone, with monitoring for post-procedural atrial fibrillation.

Blood Pressure Management

Hypertension is the single most important modifiable risk factor for recurrent stroke. The target is generally below 130/80 mmHg, supported by extrapolation from the SPRINT trial and the SPS3 data showing benefit of a target below 130 systolic in lacunar stroke. First-line agents include an ACE inhibitor or ARB combined with a thiazide diuretic; the PROGRESS trial demonstrated that perindopril plus indapamide reduced recurrent stroke by 43%. Excessive lowering should be avoided in patients with bilateral high-grade carotid stenosis or hemodynamic stroke mechanisms.

Lipid Management

All patients with atherosclerotic stroke should receive high-intensity statin therapy, specifically atorvastatin 40-80 mg or rosuvastatin 20-40 mg. The SPARCL trial showed that atorvastatin 80 mg reduced recurrent stroke by 16% and major cardiovascular events by 20% in patients with recent stroke or TIA. The LDL target is below 70 mg/dL, with some guidelines recommending below 55 mg/dL for very high-risk patients. If the LDL goal is not achieved on a maximally tolerated statin, ezetimibe or a PCSK9 inhibitor should be added, as supported by the TST trial.

Carotid Revascularization

Carotid Endarterectomy (CEA) vs Carotid Artery Stenting (CAS)

The NASCET and ECST trials established CEA as highly beneficial for symptomatic 70 to 99% stenosis (NNT of approximately 6 over 2 years), with modest benefit for 50 to 69% stenosis. The CREST trial showed that CEA and CAS had similar composite outcomes, though CEA had a lower stroke rate while CAS had a lower myocardial infarction rate; patients over age 70 favored CEA. CREST-2 is evaluating intensive medical management versus revascularization for asymptomatic carotid stenosis. Critically, CEA should be performed within 2 weeks of the index event, as benefit diminishes substantially with delay.

Diabetes Management

Glycemic targets should be individualized, with a general HbA1c goal of under 7%. Pioglitazone reduced recurrent stroke and MI in insulin-resistant patients with TIA or stroke in the IRIS trial and should be considered as adjunctive therapy. GLP-1 receptor agonists such as semaglutide and liraglutide, as well as SGLT2 inhibitors, have demonstrated cardiovascular benefit in diabetic populations.

Lifestyle Modifications

Smoking cessation is critical, as smoking doubles stroke risk, and the benefit of cessation is rapid. Patients should engage in at least 150 minutes per week of moderate-intensity exercise. A Mediterranean diet is associated with reduced vascular events, as demonstrated in the PREDIMED trial. Alcohol intake should be limited to no more than 2 drinks per day for men and 1 for women, with heavy use increasing stroke risk. Weight management targets a BMI of 18.5 to 24.9.

<image>A comprehensive secondary stroke prevention algorithm flowchart. The diagram starts with acute ischemic stroke or TIA, then branches by mechanism: (1) large artery atherosclerosis -> antiplatelet therapy (DAPT x21 days then single agent) + high-intensity statin + BP management + carotid revascularization if >=50% stenosis; (2) cardioembolic (AF) -> DOAC anticoagulation (with a comparison table of the four DOACs) + rate/rhythm control; (3) lacunar/small vessel -> single antiplatelet + aggressive BP control (<130 systolic); (4) cryptogenic -> prolonged cardiac monitoring + PFO evaluation in age <60 + antiplatelet default. All pathways converge on universal risk factor management (BP, lipids, diabetes, lifestyle).</image>

<image>A timeline graphic showing the DAPT treatment protocol after minor stroke or high-risk TIA. Day 0: event onset, start aspirin 325 mg load + clopidogrel 300 mg load. Days 1-21: aspirin 81 mg + clopidogrel 75 mg daily (benefit window from CHANCE/POINT data, shaded green). Day 22 onward: transition to single antiplatelet (clopidogrel 75 mg preferred). The CHANCE and POINT trial results are summarized below with hazard ratios for ischemic events and bleeding, showing the divergence in bleeding risk after day 21.</image>

<image>An anatomical illustration of the carotid bifurcation showing atherosclerotic plaque causing high-grade stenosis. Adjacent panels show: (1) NASCET measurement method for calculating percent stenosis, (2) comparison of CEA surgical technique (plaque removal with arteriotomy) vs CAS endovascular technique (stent deployment with embolic protection device), and (3) a summary table of NASCET/CREST outcomes including NNT and key considerations for choosing CEA vs CAS based on patient age, anatomy, and comorbidities.</image>

Clinical Pearls

Dual antiplatelet therapy with aspirin and clopidogrel should be given for exactly 21 days after minor ischemic stroke or high-risk TIA, not for 90 days, because bleeding risk rises substantially after three weeks. Apixaban is often the preferred DOAC because of its superior efficacy and lower bleeding risk compared to warfarin in the ARISTOTLE trial. Prolonged cardiac monitoring of at least 30 days, and ideally with an implantable loop recorder, should always be obtained for cryptogenic stroke before accepting an unknown etiology. PFO closure is appropriate only after rigorous exclusion of other stroke mechanisms in patients under 60 with high-risk PFO features. High-intensity statin therapy is indicated for all atherosclerotic strokes regardless of the baseline LDL level. Carotid endarterectomy should be performed within 2 weeks of the symptomatic event for maximal benefit. The SPS3 trial demonstrated that dual antiplatelet therapy is harmful in lacunar stroke, reinforcing the need for single antiplatelet therapy only in this population.

References

• Johnston SC, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA (POINT). N Engl J Med. 2018;379(3):215-225.
• Wang Y, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE). N Engl J Med. 2013;369(1):11-19.
• Mas JL, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke (CLOSE). N Engl J Med. 2017;377(11):1011-1021.
• Amarenco P, et al. High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). N Engl J Med. 2006;355(6):549-559.
• Brott TG, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis (CREST). N Engl J Med. 2010;363(1):11-23.
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among individuals with previous stroke or TIA. Lancet. 2001;358(9287):1033-1041.

Read this lecture as Markdown